Loading…
Wave Life Sciences Ltd. is projected to rise to $7.55 by 2027, a +21% move from its current price of $6.25. WVE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 15 | $6.09 | $6.25 | $6.41 | +0.02% |
| Jul 16 | $6.03 | $6.25 | $6.48 | +0.04% |
| Jul 17 | $5.98 | $6.25 | $6.54 | +0.06% |
| Jul 18 | $5.95 | $6.25 | $6.58 | +0.08% |
| Jul 19 | $5.91 | $6.26 | $6.62 | +0.10% |
| Jul 20 | $5.88 | $6.26 | $6.66 | +0.12% |
| Jul 21 | $5.85 | $6.26 | $6.69 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.85 | $6.26 | $6.69 | +0.14% |
| Week 2 | $5.70 | $6.27 | $6.89 | +0.28% |
| Week 3 | $5.59 | $6.28 | $7.05 | +0.42% |
| Week 4 | $5.49 | $6.28 | $7.19 | +0.56% |
| Week 5 | $5.42 | $6.29 | $7.31 | +0.70% |
| Week 6 | $5.35 | $6.30 | $7.43 | +0.84% |
| Week 7 | $5.28 | $6.31 | $7.54 | +0.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Wave Life Sciences Ltd. is a clinical-stage biotechnology company that designs, develops, and commercializes RNA medicines through PRISM, a discovery and drug development platform. The PRISM platform combines multiple modalities, chemistry innovation, and deep insights into human genetics to treat both rare and prevalent disorders.
The company’s portfolio includes WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated siRNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). Wave Life Sciences has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD.
Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Wave Life Sciences Ltd. (WVE) is a healthcare stock that operates in the biotechnology sector, focusing on RNA medicines via its PRISM platform. It is currently priced at $6.26 and carries a market cap of $1.2B, with a rank of 2362.
The stock’s technical backdrop shows neutral-to-mixed signals, reflecting a balance of near-term risk and potential upside. In the near term, the price trades around a level that aligns with its 50-day moving average and weighted by a broader market context.
The forecast snapshot indicates a cautious start in 2026 with an average price of $6.26, then progressively bullish outlooks from 2027 onward, culminating in a 2050 average price of $33.00 and a 2050 max of $62.32. The long-run trajectory implies meaningful upside, but with notable variability year to year.
Current indicators and the multi-year forecast suggest a path of rising averages and growing price targets, tempered by volatility and policy/clinical-development risks inherent to biotech equities.
A major floor 16.1% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 5.3% above — a clean break opens room to run.
A major ceiling 125.3% above — clearing it would confirm fresh momentum.
Key WVE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of WVE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.30 | Sell | $6.24 | Buy |
| MA 10 | $6.09 | Buy | $6.16 | Buy |
| MA 20 | $6.02 | Buy | $6.11 | Buy |
| MA 50 | $6.33 | Sell | $6.62 | Sell |
| MA 100 | $8.36 | Sell | $7.79 | Sell |
| MA 200 | $9.71 | Sell | $8.74 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.46 | Neutral |
| Stoch RSI (14) | 78.05 | Neutral |
| CCI (20) | 78.59 | Neutral |
| Williams %R (14) | -18.57 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 3.48 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 81.43 | Sell |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | 0.25 | Buy |
| Ultimate (7,14,28) | 65.23 | Neutral |
| Momentum (10) | 0.50 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 6.38 | Sell |
| ADX (14) | 15.53 | Neutral |
| ATR (14) | 0.14 | Info |
The current sentiment is NEUTRAL with RSI14 at 50. The 50-day simple moving average is $6.43 and the 200-day simple moving average is $9.72. Key support is at $5.66 and resistance at $6.58, with the 30-day range between $5.17 and $7.57.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.66 | $6.25 | $8.10 | 0% | Neutral | |
| $6.05 | $7.55 | $9.94 | +21% | Bullish | |
| $6.43 | $8.24 | $11.23 | +32% | Bullish | |
| $6.87 | $8.99 | $12.60 | +44% | Bullish | |
| $6.61 | $8.81 | $12.63 | +41% | Bullish | |
| $6.71 | $9.10 | $13.32 | +46% | Bullish | |
| $7.14 | $9.84 | $14.65 | +57% | Bullish | |
| $6.93 | $9.69 | $14.67 | +55% | Bullish | |
| $8.28 | $11.75 | $18.05 | +88% | Bullish | |
| $9.47 | $13.61 | $21.21 | +118% | Bullish | |
| $10.62 | $16.23 | $26.82 | +160% | Bullish | |
| $18.41 | $31.22 | $56.21 | +399% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.66 | $6.25 | $7.47 | +0.00% |
| August 2026 | $5.47 | $6.44 | $7.78 | +3.00% |
| September 2026 | $5.37 | $6.36 | $7.77 | -1.13% |
| October 2026 | $5.20 | $6.19 | $7.63 | -2.67% |
| November 2026 | $5.27 | $6.31 | $7.83 | +1.92% |
| December 2026 | $5.39 | $6.49 | $8.10 | +2.79% |
Click any year to see its month-by-month WVE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect WVE to range from $5.66 to $8.10 through 2026. The $6.25 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The WVE price prediction for 2027 points to an average of $7.55 (low $6.05, high $9.94) — a potential gain of +21% on today's $6.25. Momentum favours further upside here.
In 2028, WVE is projected to trade between $6.43 and $11.23, averaging $8.24 — a potential gain of +32% from today's $6.25. That is up +9% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Wave Life Sciences Ltd.'s 2029 outlook centres on $8.99, within a $6.87 to $12.60 range. That is up +9% on the projected 2028 average. That marks a +44% change versus current levels. Momentum favours further upside here.
By 2030, WVE could reach as high as $12.63, with a base case around $8.81 and support toward $6.61 — roughly +41% from $6.25. Buyers look set to stay in control over this stretch.
Expect WVE to range from $6.71 to $13.32 through 2031. The $9.10 average target implies a +46% move from current prices. That is up +3% on the projected 2030 average. Momentum favours further upside here.
The WVE price prediction for 2032 points to an average of $9.84 (low $7.14, high $14.65) — a potential gain of +57% on today's $6.25. Buyers look set to stay in control over this stretch.
In 2033, WVE is projected to trade between $6.93 and $14.67, averaging $9.69 — a potential gain of +55% from today's $6.25. That is -1% versus the projected 2032 average. Momentum favours further upside here.
Wave Life Sciences Ltd.'s 2034 outlook centres on $11.75, within a $8.28 to $18.05 range. That is up +21% on the projected 2033 average. That marks a +88% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, WVE could reach as high as $21.21, with a base case around $13.61 and support toward $9.47 — roughly +118% from $6.25. Momentum favours further upside here.
Expect WVE to range from $10.62 to $26.82 through 2040. The $16.23 average target implies a +160% move from current prices. That is up +19% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The WVE price prediction for 2050 points to an average of $31.22 (low $18.41, high $56.21) — a potential gain of +399% on today's $6.25. Momentum favours further upside here.
Investing $1,000 in WVE today (≈ 160 WVE) could be worth
$4,994.58
+$3,994.58 (+399%) by 2050 · US Dollar
Based on the average projected WVE price of $31.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in WVEwould be worth at today's price.
$1,000 invested in WVE on Jul 10, 2025 (≈ 125.786167 WVE) would be worth
$786.16
-$213.84 (-21.4%) today · 0.79× · US Dollar
Based on a WVE entry price of $7.95 vs. today's $6.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.26 | $998.4 | -0.2% |
| 1 month ago | $5.66 | $1,104.24 | +10.4% |
| 3 months ago | $7.18 | $870.47 | -13.0% |
| 6 months ago | $13.91 | $449.32 | -55.1% |
| 1 year ago | $7.95 | $786.16 | -21.4% |
| All time (5.0y) ago | $6.48 | $964.51 | -3.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our WVE forecast.
Our base-case forecast reaches $13.00 around 2035.
Implied market cap at $13.00: $2.5B
In 2026, the min, avg, and max forecast are $5.66, $6.26, and $8.26 respectively, with ROI of 0 and sentiment NEUTRAL.
From 2027 onward, the forecast turns bullish, with 2027 avg $7.76 (ROI 24) and 2028 avg $8.56 (ROI 36.7); 2029 avg $9.25 (ROI 47.7). The 2030 forecast shows avg $9.05 (ROI 44.6) and 2031 avg $9.43 (ROI 50.7), followed by 2032 avg $10.07 (ROI 60.9) and 2033 avg $9.94 (ROI 58.8).
The upside continues through 2034 with avg $12.51 (ROI 99.9) and 2035 with avg $14.40 (ROI 130.1). The multi-year horizon projects 2040 avg $17.30 (ROI 176.3) and 2050 avg $33.00 (ROI 427.1), with maxs of $62.32 in 2050. These are estimates and not guarantees, reflecting potential upside under various scenarios.
Tap a question to reveal the answer.
2030: min $6.64, avg $9.05, max $13.33; ROI 44.6%; sentiment BULLISH.
In 2026 the forecast shows avg price $6.26 with ROI 0 and NEUTRAL. From 2027 onward, the outlook is BULLISH with rising averages (e.g., 2027 avg $7.76; 2028 avg $8.56; 2029 avg $9.25) and positive ROIs (up to 50.7% in 2031 and 427.1% by 2050).
Yes—the 2050 forecast maximum is $62.32, which includes values above 50.
Current price is $6.26; Market cap is $1.2B.
RSI14 is 50; SMA50 is $6.43; SMA200 is $9.72; 30-day range is $5.17 to $7.57; support is $5.66 and resistance is $6.58.
Wave Life Sciences Ltd. Community Discussion
0Share your Wave Life Sciences Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.